Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Clot prevention--common questions about medications Tadros R; Shakib SAust Fam Physician 2010[Jul]; 39 (7): 480-3BACKGROUND: Warfarin is commonly used in a number of clinical settings. Given the difficulties in managing patients taking warfarin, several questions are usually raised by clinicians in relation to its use. OBJECTIVES: This article addresses some of the clinical questions related to warfarin use. DISCUSSION: Routine genetic testing before warfarin initiation is not currently recommended. None of the new oral anticoagulants is marketed in Australia for long term therapy as warfarin substitutes. Strategies to prevent thrombosis associated with air travel are discussed and measures to minimise the risk of bleeding are highlighted.|Anticoagulants/*therapeutic use[MESH]|Aspirin/therapeutic use[MESH]|Benzimidazoles/therapeutic use[MESH]|Dabigatran[MESH]|Factor Xa Inhibitors[MESH]|Fibrinolytic Agents/therapeutic use[MESH]|Humans[MESH]|International Normalized Ratio[MESH]|Morpholines/therapeutic use[MESH]|Pharmacogenetics[MESH]|Pyridines/therapeutic use[MESH]|Risk Factors[MESH]|Rivaroxaban[MESH]|Thiophenes/therapeutic use[MESH]|Thrombosis/*drug therapy/genetics[MESH]|Venous Thromboembolism/drug therapy/genetics[MESH] |